{"DataElement":{"publicId":"2771862","version":"1","preferredName":"Myelodysplastic Syndrome World Health Organization Classification Category","preferredDefinition":"the World Health Organization, specialized agency of the United Nations designed as a coordinating authority on international health work, classification system for myelodysplastic syndrome, a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.","longName":"MDS_WHO_CLASS_CAT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2771851","version":"1","preferredName":"Myelodysplastic Syndrome World Health Organization Classification","preferredDefinition":"information related to the World Health Organization, specialized agency of the United Nations designed as a coordinating authority on international health work, classification system for myelodysplastic syndrome, a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.","longName":"MDS_WHO_CLASS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2459218","version":"1","preferredName":"MDS","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","longName":"C3247","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F0AEBD7-94FD-60D5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2774744","version":"1","preferredName":"World Health Organization Classification","preferredDefinition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"C75419:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"World Health Organization","conceptCode":"C75419","definition":"A United Nations agency established to coordinate international health activities and to help governments improve health services.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5483FFD2-8987-0AC0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-15","modifiedBy":"ONEDATA","dateModified":"2008-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5432E3B1-3E31-3BBB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2771855","version":"1","preferredName":"Myelodysplastic Syndrome World Health Organization Classification Category","preferredDefinition":"the World Health Organization classification for myelodysplastic syndrome.","longName":"MDS_WHO_CLASS_CAT","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"85","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Refractory Anemia","valueDescription":"Refractory Anemia","ValueMeaning":{"publicId":"2771856","version":"1","preferredName":"Refractory Anemia","longName":"2771856","preferredDefinition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Anemia","conceptCode":"C2872","definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF1D-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AF36-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"Refractory Anemia with Ringed Sideroblasts","valueDescription":"Refractory Anemia with Ringed Sideroblasts","ValueMeaning":{"publicId":"2771857","version":"1","preferredName":"Refractory Anemia with Ringed Sideroblasts","longName":"2771857","preferredDefinition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.  It occurs primarily in older individuals.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts","conceptCode":"C4036","definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF42-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AF5B-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"Refractory Cytopenia with Multilineage Dysplasia","valueDescription":"Refractory Cytopenia with Multilineage Dysplasia","ValueMeaning":{"publicId":"2771858","version":"1","preferredName":"Refractory Cytopenia with Multilineage Dysplasia","longName":"2771858","preferredDefinition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines.  A minority of cases progress to acute myeloid leukemia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","conceptCode":"C8574","definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF67-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AF80-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","valueDescription":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","ValueMeaning":{"publicId":"2738442","version":"1","preferredName":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","longName":"2738442","preferredDefinition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ringed sideroblasts in the bone marrow.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia","conceptCode":"C27726","definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ring sideroblasts in the bone marrow.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-EC12-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AF95-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"Refractory anemia with excess blasts-1","valueDescription":"RAEB-1","ValueMeaning":{"publicId":"2582031","version":"1","preferredName":"RAEB-1","longName":"2582031","preferredDefinition":"A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood.  Approximately 25% of cases progress to an acute leukemia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts-1","conceptCode":"C7167","definition":"A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood.  Approximately 25% of cases progress to an acute leukemia. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Fixed the less than symbol in System Generated Value Meaning Description by removing and replacing the associated concept. dbw Dec-20-2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AFA1-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"Refractory anemia with excess blasts-2","valueDescription":"RAEB-2","ValueMeaning":{"publicId":"2582030","version":"1","preferredName":"RAEB-2","longName":"2582030","preferredDefinition":"A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood. Approximately 33% of cases progress to acute leukemia.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","conceptCode":"C7168","definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Refreshed concept association to pick up correct symbol instead of  <. 12.15.17 Updated definition to match current NCIt as requested by NMDP. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AFAD-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome, unclassified","valueDescription":"Myelodysplastic Syndrome, Unclassifiable","ValueMeaning":{"publicId":"2771859","version":"1","preferredName":"Myelodysplastic Syndrome, Unclassifiable","longName":"2771859","preferredDefinition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood;  2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Unclassifiable","conceptCode":"C8648","definition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood; 2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AFB9-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54340434-AFD2-4116-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"MDS associated with isolated del(5q)","valueDescription":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","ValueMeaning":{"publicId":"2738446","version":"1","preferredName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","longName":"2738446","preferredDefinition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with normal to increased, often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with del(5q)","conceptCode":"C6867","definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED8B-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BD076B2-1D56-6E9A-E040-BB89AD436B53","beginDate":"2008-08-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","deletedIndicator":"No"},{"value":"Chronic Myelomonocytic Leukemia","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54342348-5E48-4602-E044-0003BA3F9857","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"CAMPBELB","dateModified":"2008-08-11","deletedIndicator":"No"},{"value":"No evidence of disease","valueDescription":"No evidence of disease","ValueMeaning":{"publicId":"2570476","version":"1","preferredName":"No evidence of disease","longName":"2570476","preferredDefinition":"No evidence of disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E059-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54439523-3019-17FE-E044-0003BA3F9857","beginDate":"2008-08-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-12","modifiedBy":"ONEDATA","dateModified":"2008-08-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF09-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBREXT","dateModified":"2016-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Preferred Question Text","description":"MDS classification","url":null,"context":"CTEP"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Primary morphology of the patient's AML","url":null,"context":"COG"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"54340C95-217A-4168-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"LEEW","dateModified":"2015-05-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}